|

Investigator Choice of Bone Strengthening Agents (BSA) Clinical Trials

1 actively recruiting trial across 1 location

Also known as: Bisphosphonate, Denosumab, Ibandronate, Receptor activator of nuclear factor kappa-Β ligand (RANKL) inhibitor, Zoledronic acid

Pipeline

Phase 2: 1

Top Sponsors

  • Kelly Fitzgerald, MD1

Indications

  • Bone, Metastatic Cancer1
  • Bone Metastases of a Malignant Tumor1
  • Clear Cell Renal Carcinoma1
  • Clear Cell Renal Cell Cancer (ccRCC)1
  • Clear Cell Renal Cell Carcinoma Metastatic1

San Francisco, California1 trial

Zanzalintinib for Metastatic Clear Cell Renal Cell Carcinoma With Bone Metastases

University of California, San Francisco

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.